|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okazaki I, Ishikawa S, Ando W and Sohara
Y: Lung adenocarcinoma in never smokers: Problems of primary
prevention from aspects of susceptible genes and carcinogens.
Anticancer Res. 36:6207–6224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blevins MA, Huang M and Zhao R: The role
of CtBP1 in oncogenic processes and its potential as a therapeutic
target. Mol Cancer Ther. 16:981–990. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang R, Asangani IA, Chakravarthi BV,
Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N,
Schumann TE, et al: Role of transcriptional corepressor CtBP1 in
prostate cancer progression. Neoplasia. 14:905–914. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang XL, Huang CX, Zhang J, Inoue A, Zeng
SE and Xiao SJ: CtBP1 is involved in epithelial-mesenchymal
transition and is a potential therapeutic target for hepatocellular
carcinoma. Oncol Rep. 30:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moiola CP, De Luca P, Zalazar F, Cotignola
J, Rodriguez-Segui SA, Gardner K, Meiss R, Vallecorsa P, Pignataro
O, Mazza O, et al: Prostate tumor growth is impaired by CtBP1
depletion in high-fat diet-fed mice. Clin Cancer Res. 20:4086–4095.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raza U, Saatci O, Uhlmann S, Ansari SA,
Eyupoglu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD,
et al: The miR-644a/CTBP1/p53 axis suppresses drug resistance by
simultaneous inhibition of cell survival and epithelial-mesenchymal
transition in breast cancer. Oncotarget. 7:49859–49877. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao C, Shen Y, Tao X, Xu J, Lu J, Liu C,
Xu Z, Tang Q, Tao T and Zhang X: Silencing of CtBP1 suppresses the
migration in human glioma cells. J Mol Histol. 47:297–304. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng Y, Deng H, Liu J, Han G, Malkoski S,
Liu B, Zhao R, Wang XJ and Zhang Q: Transcriptional down-regulation
of Brca1 and E-cadherin by CtBP1 in breast cancer. Mol Carcinog.
51:500–507. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han Y, Bi Y, Bi H, Diao C, Zhang G, Cheng
K and Yang Z: miR-137 suppresses the invasion and procedure of EMT
of human breast cancer cell line MCF-7 through targeting CtBP1. Hum
Cell. 29:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cui T, Srivastava AK, Han C, Yang L, Zhao
R, Zou N, Qu M, Duan W, Zhang X and Wang QE: XPC inhibits NSCLC
cell proliferation and migration by enhancing E-cadherin
expression. Oncotarget. 6:10060–10072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hugo HJ, Gunasinghe NPAD, Hollier BG,
Tanaka T, Blick T, Toh A, Hill P, Gilles C, Waltham M and Thompson
EW: Epithelial requirement for in vitro proliferation and xenograft
growth and metastasis of MDA-MB-468 human breast cancer cells:
Oncogenic rather than tumor-suppressive role of E-cadherin. Breast
Cancer Res. 19:862017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen S, Li X, Lu D, Xu Y, Mou W, Wang L,
Chen Y, Liu Y, Li X, Li LY, et al: SOX2 regulates apoptosis through
MAP4K4-survivin signaling pathway in human lung cancer cells.
Carcinogenesis. 35:613–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bora-Singhal N, Perumal D, Nguyen J and
Chellappan S: Gli1-Mediated regulation of Sox2 facilitates
self-renewal of stem-like cells and confers resistance to EGFR
Inhibitors in non-small cell lung cancer. Neoplasia. 17:538–551.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Q, Liu F, Zhang Y, Fu L, Wang C, Chen
X, Guan S and Meng X: Association of SOX2 and Nestin DNA
amplification and protein expression with clinical features and
overall survival in non-small cell lung cancer: A systematic review
and meta-analysis. Oncotarget. 7:34520–34531. 2016.PubMed/NCBI
|
|
18
|
Wang L, Yang H, Lei Z, Zhao J, Chen Y,
Chen P, Li C, Zeng Y, Liu Z, Liu X and Zhang HT: Repression of
TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal
transition in non-small-cell lung cancer. Oncogene. 35:867–877.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sholl LM, Barletta JA, Yeap BY, Chirieac
LR and Hornick JL: Sox2 protein expression is an independent poor
prognostic indicator in stage I lung adenocarcinoma. Am J Surg
Pathol. 34:1193–1198. 2010. View Article : Google Scholar : PubMed/NCBI
|
